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OBJECTIVEdThe implications of celiac disease (CD) in adult patients with type 1 diabetes are
unknown, with respect to diabetes-related outcomes including glycemic control, lipids, microvas-
cular complications, quality of life, and the effect of a gluten-free diet (GFD). We identiﬁed CD in
adults with type 1 diabetes and investigated the effect of a GFD on diabetes-related complications.
RESEARCH DESIGN ANDMETHODSdThis was a case-control study conducted at a
U.K. teaching hospital. Patients with type 1 diabetes aged .16 years (n = 1,000) were assessed
for CD. HbA1c, lipid proﬁle, quality of life, retinopathy stage, nephropathy stage, and degree of
neuropathy before and after 1 year on a GFD were assessed.
RESULTSdThe prevalence of CD was 33 per 1,000 subjects (3.3% [95% CI 2.3–4.6]). At
diagnosis of CD, adult type 1 diabetic patients had worse glycemic control (8.2 vs. 7.5%, P =
0.05), lower total cholesterol (4.1 vs. 4.9, P = 0.014), lower HDL cholesterol (1.1 vs. 1.6, P =
0.017), and a higher prevalence of retinopathy (58.3 vs. 25%, P = 0.02), nephropathy (41.6 vs.
4.2%, P = 0.009), and peripheral neuropathy (41.6 vs. 16.6%, P = 0.11). There was no difference
in quality of life (P. 0.1). After 1 year on a GFD, only the lipid proﬁle improved overall, but in
adherent individuals HbA1c and markers for nephropathy improved.
CONCLUSIONSdAdults with undetected CD and type 1 diabetes have worse glycemic
control and a higher prevalence of retinopathy and nephropathy. Treatment with a GFD for
1 year is safe in adults with type 1 diabetes and does not have a negative impact on the quality of life.
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Long-term microvascular and neuro-logic complications are responsiblefor major morbidity and mortality in
type 1 diabetes (1). Intensive glycemic
control reduces these complications and
improves quality of life (1). Even patients
with good glycemic control have comp-
lications, suggesting that other factors in-
crease the risk (2). Coexisting medical
problems may be a confounding factor
when managing glycemic control (2). The
association between celiac disease (CD)
and type 1 diabetes was recognized over
30 years ago, particularly by pediatricians.
The prevalence of CD in patients with
adult type 1 diabetes has been reported
as 1.8–8.4% (3–6). Despite a large num-
ber of prevalence studies, other important
clinical factors have not been well investi-
gated, including glycemic control, quality
of life, microvascular complications, car-
diac risk factors, and bone mineral density.
Investigations of the effect of CD on
glycemic control have been conﬂicting,
with some studies showing improvement
(7) and some deterioration (4,8) and others
showing no effect (9). The difﬁculty in
interpreting these studies is that most in-
volve pediatric populations and are small,
retrospective, and uncontrolled, leaving
this question unanswered. There have
been no quality-of-life assessments be-
fore and after the diagnosis of CD to as-
sess the impact of the diagnosis and a
subsequent gluten-free diet (GFD) (3).
Adapting to a GFD with the restrictions
of a diabetic diet may negatively impact
quality of life.
Peripheral neuropathy affects up to
30% of patients with adult type 1 diabetes
and is a major cause of morbidity (1).
Neuropathy is associated with both type 1
diabetes and CD; therefore, patients with
both conditions may have a higher preva-
lence (10,11). In gluten-sensitive neurop-
athy, the pathophysiological changes lie
in the humoral immune response, and a
GFD seems to be beneﬁcial (12,13). There
are no studies examining neuropathy in
patients with type 1 diabetes and CD or
the effect of a GFD. One study examined
whether CD may contribute to autonomic
neuropathy in a cohort of patients with
type 1 diabetes. They found no difference
in the prevalence of positive antibodies in
patients with and without autonomic neu-
ropathy (14).
Two previous studies have examined
the effect of CD on diabetic nephropathy
but were conﬂicting (15,16). There are
currently no studies examining the prev-
alence of retinopathy in individuals with
both type 1 diabetes and CD.
Recent data in nondiabetic CD cohorts
have shown a reduced risk of ischemic
heart disease, possibly attributed to lower
cholesterol levels and a lower prevalence of
hypertension (17). Reduced bone mineral
density has been associated with both CD
and type 1 diabetes, but there are little data
on people with both conditions (18). The
aim of our studywas to identify undetected
CD in adult patients with type 1 diabetes
and investigate the effect on diabetes-
related complications before and after a
GFD.
RESEARCH DESIGN AND
METHODSdThe Shefﬁeld Diabetes
Centre operates at both the Royal Hallam-
shire Hospital and the Northern General
c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c
From the 1Gastroenterology and Liver Unit, Royal Hallamshire Hospital, Shefﬁeld, U.K.; the 2Department
of Neurology, Royal Hallamshire Hospital, Shefﬁeld, U.K.; and the 3Department of Diabetes, Royal
Hallamshire Hospital, Shefﬁeld, U.K.
Corresponding author: John S. Leeds, jsleeds@hotmail.com.
Received 23 January 2011 and accepted 1 July 2011.
DOI: 10.2337/dc11-0149
 2011 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and thework is not altered. See http://creativecommons.org/
licenses/by-nc-nd/3.0/ for details.
2158 DIABETES CARE, VOLUME 34, OCTOBER 2011 care.diabetesjournals.org
C l i n i c a l C a r e / E d u c a t i o n / N u t r i t i o n / P s y c h o s o c i a l R e s e a r c h
O R I G I N A L A R T I C L E
Hospital. This covers a population of
~500,000 people and provides tertiary
referral services for the South Yorkshire
region. There are ~2,000 patients with
type 1diabetes, deﬁnedusing theAmerican
Diabetes Association position statement.
Approximately 95% of patients with type 1
diabetes aremanaged by the diabetes center
in secondary care.
Inclusion criteria were patients with
type 1 diabetes aged.16 years. Exclusion
criteria were patients aged ,16 years, in-
ability to consent, or afﬂiction with diabe-
tes other than type 1. Where diabetes type
was uncertain, the notes were reviewed
with the treating consultant and a decision
made concerning diabetes type. If diabetes
type still was uncertain, then the individ-
ual was excluded.
Patients were prospectively recruited
when attending for annual review, the
foot clinic, or the Dose Adjustment for
Normal Eating Clinic. Study participants
completed a health questionnaire and the
short-form 36 (version 2) quality-of-life
assessment questionnaire (Quality Metric).
Data were prospectively collected, includ-
ing age, sex, ethnicity, drug history, and
other medical comorbidities. Blood was
taken for glycosylated hemoglobin (HbA1c),
renal proﬁle, lipid proﬁle (including total
and HDL cholesterol), full blood count,
IgA endomysial antibody (EMA), IgA
anti-tissue transglutaminase antibody
(tTG), and total IgA levels.
Diagnosing CD
Participants with either a positive anti-
body or a low IgA level were recalled and
offered a duodenal biopsy. Histological
features consistent with CD were classiﬁed
according to Marsh staging (0–3), with
grade 3 changes (villous atrophy) consid-
ered diagnostic of CD (19).
Newly identiﬁed CD study group
investigations
Participants with newly identiﬁed CD
underwent additional investigations to
determine the effect of unrecognized CD.
In addition to HbA1c (measured by boro-
nate afﬁnity chromatography and high-
performance liquid chromatography),
quality-of-life assessment, and lipid proﬁle,
assessment of microvascular complications
and bone mineral density were made.
The presence of nephropathy was as-
sessed using renal protein excretion,
estimated glomerular ﬁltration rate
(eGFR), and diabetes nephropathy stage.
Renal protein excretion was measured us-
ing the urinary protein-to-creatinine ratio
(albumin-to-creatinine ratio [ACR]), and
eGFR was calculated and a chronic kidney
disease stage was assigned. Retinopathy
was assessed by notes review and graded
as no retinopathy, background changes,
preproliferative changes, or proliferative
changes, as described by the National
Screening Committee for Diabetic Retinop-
athy. Patients underwent annual retinal
photography and were reviewed within
3months of diagnosis and then 1 year later.
Peripheral neuropathy was assessed
by a combination of quantitative sensory-
threshold tests, cardiac autonomic func-
tion tests, and electrophysiological tests
of four nerves. Quantitative sensory-
threshold tests were performed using the
Computer-Aided Sensory Evaluator (CASE
IV version 4.27), which provides cold,
vibration, and heat-pain detection thresh-
olds on the dorsum of the right foot.
Cardiovascular autonomic function
tests were measured using the O’Brien
protocol. A three-lead electrocardiogram
was attached to the subject while lying in
the supine position. After a rest period,
measurements of the time between R
waves on the electrocardiogram were
made, and changes in heart rate based on
RR variation over time were recorded. The
degree of variation was calculated using the
RR ratio and was corrected for age. RR ra-
tios were measured at rest, during deep
breathing, during the Valsalva maneuver,
and after rising from the supine position.
The change in blood pressure from lying
down to standing also was measured. Au-
tonomic dysfunction was diagnosed if two
or more of these tests were abnormal.
Electrophysiological tests were per-
formed on the radial nerve, sural nerve,
common peroneal nerve, and the tibial
nerve using surface electrodes (Synergy
version 10.0; Oxford Instruments). The
nerves were subjected to supramaximal
stimulation to allow measurement of the
amplitude and latency. Neuropathic symp-
toms were assessed using the Neuropathy
Symptom Score (20) and the Neuropathic
Impairment Score of the Lower Limbs
(NISLL) questionnaires. The NISLL+7
score was calculated to determine the
presence and severity of neuropathy for
comparison between groups (20).
Bone mineral density was assessed
using dual-energy X-ray absorptiometry
(DEXA). In the previously undetected CD
patients with type 1 diabetes, these meas-
urements were made prior to starting a
GFD. Apart frombonemineral density, all
measurements were repeated at 1 year of
following a GFD.
Control groups
The control population to compare the
prevalence of CD was taken from screen-
ing 1,200 healthy volunteers recruited
from ﬁve separate general practices in
Shefﬁeld. These ﬁve practices serve dif-
ferent socioeconomic backgrounds. These
individuals were a mix of patients attend-
ing the practice and those attending with
a patient to reduce bias from health care–
seeking behavior. These individuals repre-
sent a similar group because the majority
of patients with type 1 diabetes are seen as
“well” outpatients. This population has
been previously described (21).
To provide control subjects for sub-
jects with type 1 diabetes and newly
identiﬁed CD, individuals from the type
1 diabetic cohort without CD were ran-
domly selected from those who matched
by age, sex, weight, and diabetes dura-
tion, with a ratio of two control subjects to
one case subject. These individuals also
underwent the same additional investiga-
tions (with the exception of DEXA scan-
ning), and comparisons were made at
baseline and 1 year.
Statistical analysis and power
calculation
Statistical analyses were performed using
SPSS version 13.0. A comparison of the
prevalence of CD between cohorts was
performed using a Fisher exact test, and
odds ratios were calculated. A comparison
of clinical parameters was performed using
the Mann-Whitney U test at both baseline
and 1 year. Comparisons of changes in
parameters within each group over time
were performed using the Wilcoxon
signed-rank test.
Assuming that the prevalence of CD is
1% for the control subjects (21) and the
prevalence of CD in patients with type 1
diabetes is 3%, a sample size of 1,000 will
give 85% power to detect a difference at
the P = 0.05 level. Assuming that the prev-
alence of neuropathy is 30% in patients
with type 1 diabetes and 50% in patients
with type 1 diabetes and CD, a sample size
of 50 will give 90% power to detect a dif-
ference at the P = 0.05 level. To determine
whether there were differences in the
progression of neuropathy (and subsequent
outcomes on a GFD) between patients
with type 1 diabetes and CD compared
with control subjects, the Wilcoxon
signed-rank test was used. Assuming a
two-point difference in the mean composite
score between case and control subjects, a
sample size of 50 will have 95% power to
detect a difference at the P = 0.05 level.
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Ethical approval
Ethical approval was obtained from the
South Shefﬁeld Research Ethics Commit-
tee, and written informed consent was
obtained.
RESULTSdFigure 1 shows the ﬂow of
participants through the study. A total
of 1,043 individuals were approached,
of which 1,000 agreed to take part
(95.8% uptake). The mean age of the
group was 43.2 years, and there were
439 female subjects. During this period,
21 individuals were identiﬁed with estab-
lished CD and type 1 diabetes. These pa-
tients had been identiﬁed as a result of
overt gastrointestinal symptoms or gross
anemia. They were included in the anal-
ysis to enable the calculation of the prev-
alence of CD in the entire cohort.
Serological results
We diagnosed 12 new cases of undetected
CD (Fig. 1), of which 6 had gastrointesti-
nal symptoms, 4 were anemic, and 2 were
negative for EMA. With the inclusion
of the 21 patients with established CD
(already on a GFD) identiﬁed during the
period of study, the prevalence of CD in
this cohort of people with type 1 diabetes
was 3.3% (33 of 1,000) (95%CI 2.3–4.6).
Compared with the population control
group (21), in which the prevalence of
CD was 1% (12 of 1,200) (0.5–1.7), there
was an increased prevalence of CD in
people with type 1 diabetes (odds ratio
3.3 [95% CI 1.7–6.6], P , 0.0001).
There were four patients with positive
antibodies who refused to be biopsied. If
these individuals had undergone investiga-
tion, and if all four were found to have CD,
then the prevalence would have been 3.7%
(37 of 1,000) (95% CI 2.6–5.1).
A total of 21 patients tested positive
for EMA but had nondiagnostic biopsies
and were considered to have potential
CD and entered into clinical follow-up. A
total of 18 of these individuals had com-
pletely normal biopsies, whereas 3 indi-
viduals had increased intraepithelial
lymphocyte counts (Marsh grade 1). These
individuals were excluded from the subse-
quent investigations in the study because
they did not meet the diagnostic criteria
for CD.
Newly identiﬁed CD comparisons
The case (n = 12) and control (n = 24)
subjects were well matched for age, sex,
diabetes duration, average insulin dose,
and weight at baseline. Table 1 summa-
rizes the observations in those with both
type 1 diabetes and CD and control sub-
jects at baseline and after 1 year on a
GFD. Table 2 summarizes the observa-
tions in those with type 1 diabetes and
CD stratiﬁed by adherence to the GFD at
1 year.
At baseline, individuals with type 1
diabetes and CD had higher HbA1c, lower
total cholesterol, lower HDL cholesterol,
lower diastolic blood pressure, and a
higher prevalence of advanced nephrop-
athy and retinopathy. There was a trend
toward higher urinary protein excretion
and peripheral neuropathy. There was no
difference in quality of life in any of the
domains (all P . 0.1), the cholesterol-to-
HDL ratio, triglycerides, sensory detection
thresholds, autonomic function testing,
electrophysiological testing, or NISLL+7
scores (12.5 vs. 11.0, P = NS).
After 1 year on a GFD for individuals
with type 1 diabetes and recently detected
CD, there was no longer a difference in
HbA1c, blood pressure, or prevalence of
nephropathy. Of interest, there was clin-
ically signiﬁcant improvement in the pre-
valence of advanced nephropathy after
1 year on a GFD. This occurred as three
patients had improvements in their renal
protein excretion, but this did not achieve
statistical signiﬁcance (P . 0.1). There
was a trend toward lower total choles-
terol, lower HDL cholesterol, and periph-
eral neuropathy. There still was a higher
prevalence of advanced retinopathy.
Quality-of-life scores at 1 year were not
signiﬁcantly different compared with
baseline (all P . 0.1).
Outcomes also were stratiﬁed by ad-
herence to the GFD, as judged by positive
antibodies at 1 year (positive for EMA or
tTG .15), clinical assessment with the
patient, and dietetic review. Nine individ-
uals were judged to be adherent to the
diet, and these data are shown in Table 2.
In these groups, the difference in the base-
line and 1-year value for each variable was
calculated and averaged, showing the
mean direction of change with respect to
adherence to the GFD. Those judged ad-
herent to the GFD had a signiﬁcant in-
crease in HDL cholesterol compared
with those who were not. Also, HbA1c,
the cholesterol-to-HDL ratio, triglycer-
ides, and urinary ACR changed favorably
in adherent individuals, whereas these
changes were unfavorable or less marked
in the nonadherent subjects. These num-
bers are very small and therefore must be
interpreted with caution.
Figure 1dStudy participant ﬂow diagram. Four individuals refused the duodenal biopsy (all
were positive for EMA/tTG).
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Other factors
At the 1-year follow-up, there were no
signiﬁcant differences between case and
control subjects when comparing age,
sex, diabetes duration, and average in-
sulin dose or weight. Analysis of these
factors by comparing them with baseline
values found no signiﬁcant changes in
those with both type 1 diabetes and CD,
but there was a trend toward weight gain
in the control group (72.3 vs. 77.5 kg, P =
0.053).
Bone mineral density
All patients with newly identiﬁed CD were
sent for a DEXA scan to assess bonemineral
density. A total of 3 of 12 individuals had
abnormal bone mineral density, with 2 of
12 (16.7%) having osteoporosis and 1 of
12 (8.3%) having osteopenia.
CONCLUSIONSdThis is theﬁrst study
to assess the effect of newly diagnosed CD
in adultswith type 1 diabetes and to provide
follow-up of important clinical outcomes
on a GFD. Prior to starting a GFD, case and
control subjects were well matched for age,
sex, weight, average insulin dose, and
duration of diabetes. At baseline, people
with both type 1 diabetes and undetected
CD had signiﬁcantly worse glycemic con-
trol, lower total cholesterol, lower HDL
cholesterol, lower diastolic blood pressure,
more renal disease, and more retinopathy
compared with control subjects.
After 1 year on a GFD, the only differ-
ence was the prevalence of advanced reti-
nopathy. Adherent individuals had a
signiﬁcant increase in HDL cholesterol and
favorable changes in parameters, such as
glycemic control and renal protein excre-
tion. There was no detriment of a GFD in
type 1 diabetes, particularly in glycemic
control, in keeping with previous studies
(4,9).
Quality of life showed no differences
at baseline or following a GFD. Improve-
ment in gastrointestinal symptoms needed
balancing against a more complicated diet,
and improvements in HbA1c were modest.
Social isolation as a result of the GFD has
been previously described (22).
The ﬁnding of increased prevalence of
microvascular complications is novel. With
respect to nephropathy, people with both
type 1 diabetes and CD had signiﬁcantly
higher ACRs at baseline, and a trend re-
mained at 1 year, with eGFR being reduced
signiﬁcantly compared with control sub-
jects. Two patients had signiﬁcant deterio-
ration in their renal proﬁle, with one
starting dialysis.
There are two studies examining the
association of CD and diabetic nephrop-
athy. A study of 967 people with type 1
diabetes, of which 462 had nephropathy,
found no difference in the prevalence of
CD (15). A study of children with type 1
diabetes and established CD on a GFD
Table 1dSummary of the ﬁndings at baseline and 1 year following a GFD in case and
control subjects
Variables CD and type 1 diabetes Control subjects P
Baseline values
Age (years) 41 41 NS
Duration (years) 22.5 28.5 NS
Weight (kg) 71 72.3 NS
Insulin dose (units/kg) 0.69 0.66 NS
HbA1c (%) 8.2 (2.5) 7.5 (1.93) 0.05
Cholesterol (mmol/L) 4.1 (1.43) 4.9 (1.13) 0.014
HDL (mmol/L) 1.1 (0.6) 1.56 (0.8) 0.017
Cholesterol-to-HDL ratio 3.4 (1.7) 2.8 (1.8) NS
Triglycerides (mmol/L) 0.85 (0.8) 0.75 (0.6) NS
eGFR 95.5 (35.8) 89.5 (28.3) NS
ACR 1.8 (36.2) 1.0 (2.0) 0.06
Nephropathy stage .3 [n (%)] 5/12 (41.6) 1/24 (4.2) 0.009
Advanced retinopathy [n (%)] 7/12 (58.3) 6/24 (25) 0.02
Peripheral neuropathy [n (%)] 5/12 (41.6) 4/24 (16.6) 0.11
1-Year values
Weight (kg) 69.9 77.5 NS
Insulin dose (units/kg) 0.69 0.64 NS
HbA1c (%) 8.5 (1.65) 8.45 (1.5) NS
Cholesterol (mmol/L) 4.1 (1.2) 4.8 (1.25) 0.08
HDL (mmol/L) 1.2 (0.6) 1.6 (0.8) 0.07
Cholesterol-to-HDL ratio 3.4 (1.5) 2.8 (1.9) NS
Triglycerides (mmol/L) 0.85 (0.4) 0.65 (0.7) NS
eGFR 84.0 (31.0) 87.5 (33.0) NS
ACR 1.5 (10.0) 0.5 (0.8) NS
Nephropathy stage .3 [n (%)] 2/12 (16.6) 1/24 (4.2) NS
Advanced retinopathy [n (%)] 7/12 (58.3) 6/24 (25) 0.02
Peripheral neuropathy [n (%)] 5/12 (41.6) 4/24 (16.6) 0.11
Data are median (interquartile range), unless otherwise indicated. NS, not signiﬁcant.
Table 2dFindings at follow-up stratiﬁed by compliance to the GFD in those with type 1
diabetes and CD
Variables Adherence Poor Adherence P
HbA1c (%) 8.5 9.1 NS
Mean difference 20.98 +0.85 NS
Total cholesterol (mmol/L) 4.0 4.0 NS
Mean difference +0.2 20.45 NS
HDL cholesterol (mmol/L) 1.2 1.4 NS
Mean difference +0.3 20.2 0.029
Cholesterol-to-HDL ratio 3.4 2.9 NS
Mean difference 20.6 0.0 NS
Triglycerides (mmol/L) 0.9 0.8 NS
Mean difference 20.6 20.3 NS
eGFR 84 70 NS
Mean difference 215 211 NS
ACR 1.0 1.3 NS
Mean difference 27.4 +5.8 NS
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was compared with a control group with
diabetes alone. Those with CD had lower
urinary protein loss, suggesting that a
GFD was protective (16). Our results are
in keeping with Malalasekera et al. (16),
who suggest that dietary modiﬁcations
of a GFD might be beneﬁcial and a re-
duced dietary intake of advanced glyca-
tion end products may be responsible.
Recent epidemiological studies sug-
gest that patients with CD have a lower
risk of developing ischemic heart disease,
possibly as a result of lower cholesterol
levels (17). Another study showed that in
newly diagnosed CD, total cholesterol
was lower at diagnosis and after 12months
on a GFD, and despite no change in total
cholesterol, HDL cholesterol increased by
an average of 12% (23). This is more im-
portant for patients at increased cardiac
risk, such as those with type 1 diabetes.
Renal and retinal changes commonly
mirror each other and are related to un-
derlying endothelial dysfunction. The prev-
alence of retinopathy was similar in people
with type 1 diabetes and undetected CD
compared with control subjects, but the
prevalence of more advanced retinopathy
was signiﬁcantly higher in the CD group,
with one subject undergoing laser therapy.
An association between CD and neu-
ropathy has been previously described
but not in the context of type 1 diabetes
(10,11). We found that individuals with
newly identiﬁed CD and type 1 diabetes
had a higher prevalence of neuropathy,
but this was not statistically signiﬁcant.
After 1 year on a GFD, there was no sig-
niﬁcant improvement of the neuropathy.
This may be because of the short period of
follow-up or because the impact of diabetes
on peripheral nerve damage is more sub-
stantial than CD (1,2). It would be inter-
esting to follow-up this cohort of patients
to see whether their neuropathy eventu-
ally improves. All newly identiﬁed CD pa-
tients had micronutrients, such as vitamin
B12 and folic acid, measured, which were
normal. One previous study examined the
prevalence of positive tTG antibodies in
patients with type 1 diabetes with and
without autonomic neuropathy (judged
by cardiac reﬂex testing and gastric scintig-
raphy). They found no difference in the
prevalence of positive tTG antibodies in
those with and without autonomic neu-
ropathy. This study has limitations in
that it is unclear whether the two groups
were matched for similar clinical charac-
teristics; only one individual had
a duodenal biopsy conﬁrming CD, and
longitudinal follow-up is only described
in this patient (14). In our study, there
was no difference in the prevalence of au-
tonomic neuropathy in those with and
without CD. Changes in blood glucose lev-
els may be secondary to gastrointestinal
motor dysfunction, as occurs in diabetic
gastroparesis, which may be compoun-
ded by similar ﬁndings described in CD.
No study has compared the rate of the de-
velopment of autonomic neuropathy in
patients with type 1 diabetes and CD
compared with those with type 1 diabetes
alone.
The mechanism by which CD increa-
ses the risk of microvascular disease is
unclear and is likely to be multifactorial.
Unrecognized CD is associated with raised
homocysteine levels, which is probably a
result of deﬁciency in folic acid and other
B vitamins, which is a risk factor for en-
dothelial dysfunction (24). A recent study
showed that supplementation of vitamin
B in CD was associated with signiﬁcantly
lower homocysteine levels, potentially re-
ducing the risk of vascular disease (25). In
the current study, the combination of
higher HbA1c and lower HDL cholesterol,
possibly secondary to underlying chronic
inﬂammation, may be the mechanism.
Improvement of these parameters after 1
year on a GFD is encouraging and similar
to that seen in newly diagnosed CD with-
out diabetes.
Additional studies are required to
determine whether early detection of CD
in type 1 diabetes and treatment with a
GFD affects the development of micro-
vascular complications. Follow-up of the
current study group over several years
also may provide additional insight into
the interplay between type 1 diabetes and
CD. Such investigations are likely to be
more informative if conducted in a mul-
ticenter fashion with a larger study pop-
ulation and corresponding control group.
In summary, this is the ﬁrst study to
assess the effects of undetected CD in
adult patients with type 1 diabetes. These
individuals have worse glycemic control
and a higher prevalence of retinopathy
and nephropathy. Treatment with a GFD
is safe and does not impact quality of life.
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